# 16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis

> **NCT01649375** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 219 (actual)

## Conditions studied

- Anklyosing Spondylitis

## Interventions

- **DRUG:** Secukinumab (75 mg)
- **DRUG:** Placebo
- **DRUG:** Secukinumab (150 mg)

## Key facts

- **NCT ID:** NCT01649375
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-18
- **Primary completion:** 2014-08-04
- **Final completion:** 2018-09-18
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2019-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01649375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01649375, "16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01649375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*